Search

Corvus Pharmaceuticals Inc

Uždarymo kaina

14 -2.1

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

14.1

Max

14.56

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-1.4M

-14M

Pelnas, tenkantis vienai akcijai

-0.15

Darbuotojai

37

EBITDA

312K

-12M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+118.38% upside

Dividendai

By Acuity

Kitas uždarbis

2026-08-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-161M

1.2B

Ankstesnė atidarymo kaina

16.1

Ankstesnė uždarymo kaina

14

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-21 23:56; UTC

Fair Isaac Corp shares are higher in after-market trading, supported by positive investor sentiment and a notable rise in the Nikkei 225 Index.

2026-07-21 23:56; UTC

Ulta Beauty Inc. shares are lower in after-market trading, reflecting broader market trends despite positive sentiment from the Nikkei 225 Index surge.

2026-07-21 23:56; UTC

American Electric Power shares are lower in after-market hours, continuing a three-session decline and remaining below the 20-day moving average.

2026-07-21 23:56; UTC

Mondelez International shares declined in after-market trading, continuing a trend of four consecutive lower daily closes despite earlier gains during the session.

2026-07-21 23:56; UTC

Northern Trust shares are higher in after-market trading, reflecting broader positive trends in regional equity indices and renewed investor optimism.

2026-07-21 23:56; UTC

Dorian LPG Ltd shares are trading higher in after-market hours, reflecting a gradual increase since Tuesday's close amid broader positive trends in regional equity indices.

2026-07-21 23:56; UTC

Macro News
ETF Constituents
Correlated Moves

U.S. stock markets rebounded, with the Financial Select Sector SPDR Fund roughly flat in after-hours trading, supported by contributions from SCHW, ICE, FISV, AON, and AXP.

2026-07-21 23:56; UTC

No specific news was identified for Alnylam Pharmaceuticals during after-market hours. The stock remains near unchanged since Tuesday's close.

2026-07-21 23:56; UTC

Phillips 66 shares are higher in after-market trading, with no specific news identified. Broader market momentum reflects positive investor sentiment amid easing geopolitical tensions.

2026-07-21 23:56; UTC

Shake Shack Inc. shares are higher in after-market trading, reflecting a modest gain amid positive sentiment from broader market trends, including a rise in the Nikkei 225 Index.

2026-07-21 23:56; UTC

Diamondback Energy Inc shares are lower in after-market hours, continuing a decline since Tuesday's close. Trading has reflected overall weaker performance without specific news.

2026-07-21 23:56; UTC

Lumen Technologies Inc. shares are higher in after-market hours, reflecting a modest gain amid broader market weakness and positive sentiment in regional equity indices.

2026-07-21 23:56; UTC

Baidu Inc. shares declined in after-market trading, retracing from an early session peak and remaining below recent averages. No specific news was identified.

2026-07-21 23:56; UTC

Southern Copper Corp shares are lower in after-market trading, retracing from earlier gains while remaining above their 20-day moving average.

2026-07-21 23:56; UTC

Entegris Inc shares are higher in after-market trading, reflecting a notable gain since Tuesday's close amid positive sentiment in regional equity indices.

2026-07-21 23:56; UTC

ETF Constituents

Health Care Select Sector SPDR Fund declines after market close, driven by negative returns from Merck, Amgen, and Eli Lilly. The ETF remains near its one-month trading range.

2026-07-21 23:52; UTC

Kratos Defense shares are higher in after-market trading, rebounding from earlier losses despite no specific news to explain the movement.

2026-07-21 23:51; UTC

Japan's Trade Deficit Expected at -120 Billion Yen Amid Ongoing Economic Challenges and Investor Caution.

2026-07-21 23:51; UTC

Japan's June export growth forecasted at 0.186%, crucial for GDP amid stable market expectations and global supply chain challenges.

2026-07-21 23:51; UTC

Brazil's Central Bank Signals Potential Interest Rate Cuts Amid Lower Inflation Expectations Ahead of Key COPOM Meeting on July 27, 2026.

2026-07-21 23:51; UTC

iShares Core U.S. Aggregate Bond ETF is trading higher in after-market hours amid a general upward trend in global equity indices and positive sentiment in fixed income.

2026-07-21 23:51; UTC

News

Regeneron Pharmaceuticals faces a class action lawsuit for securities fraud over misleading claims about Fianlimab-Libtayo trial results. Shares are lower in after-hours trading.

2026-07-21 23:51; UTC

Yum China Holdings Inc. shares rose in after-market trading, buoyed by positive market sentiment following earnings reports from Tesla and Broadcom.

2026-07-21 23:51; UTC

Recursion Pharmaceuticals Inc's shares are lower in after-market hours, settling down from Tuesday's close without any specific news to explain the movement.

2026-07-21 23:51; UTC

Zeta Global Holdings is higher in after-market trading, amid broader market strength following positive earnings from companies like Tesla and Broadcom.

2026-07-21 23:51; UTC

Intercontinental Exchange Inc shares are higher in after-market hours amid increased trading activity, remaining above their 20-day moving average and near a one-month high.

2026-07-21 23:51; UTC

Coca-Cola Europacific Partners PLC shares are lower in after-market hours amid notable volatility, with no specific company news identified to explain the movement.

2026-07-21 23:51; UTC

Starwood Property Trust shares rose in after-market trading amid positive market sentiment following earnings reports from companies like Tesla and Broadcom.

2026-07-21 23:51; UTC

NetEase Inc. shares are higher in after-market trading, reflecting positive sentiment from recent earnings reports of firms like Tesla and Broadcom.

2026-07-21 23:51; UTC

Correlated Moves

Nexgen Energy Ltd shares advanced in after-market trading, buoyed by positive sentiment following earnings reports from major companies like Tesla and Broadcom.

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

118.38% į viršų

12 mėnesių prognozė

Vidutinis 31.6 USD  118.38%

Aukščiausias 40 USD

Žemiausias 27 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

5

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat